Abbott Laboratories

ABT • Medical - Devices

$108.32

▼ -0.47 (-0.43%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$188.80B

Crecimiento

6.8%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 14.7%Flujo de caja libre positivo · 4.23Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.29Liquidez saludable · 1.58

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$108.32

Change-0.43%

Shares Out1.74B

Market Cap$188.80B

Enterprise Value$215.81B

52W Range81.97 - 137.49

Beta0.61

P/E34.80

P/S4.05

P/B2.89

P/FCF21.65

EV/Sales4.63

Price$108.32

Change-0.43%

Shares Out1.74B

Market Cap$188.80B

Enterprise Value$215.81B

52W Range81.97 - 137.49

Beta0.61

P/E34.80

P/S4.05

P/B2.89

P/FCF21.65

EV/Sales4.63

EV/EBITDA22.63

EV/FCF24.75

Earnings Yield2.87%

FCF Yield4.62%

Dividend Yield1.67%

Gross Margin55.51%

Oper. Margin18.16%

Profit Margin14.72%

Debt/Eq0.29

Current Ratio1.58

Quick Ratio1.18

Revenue 5Y6.83%

Target$123.64

Target Upside14.14%

Target Median$121.00

Target Range92.00 - 145.00

Volume9.14M

Avg Volume13.39M

EPS Surprise0.01

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

68/100

Fortaleza financiera

Deuda, caja, estabilidad

87/100

Potencial de crecimiento

Ingresos y expansión

26/100

Atractivo del precio

Barata o cara hoy

52/100

Por qué este puntaje▼

Márgenes estables o en mejora · 14.7%Flujo de caja libre positivo · 4.23Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.29Liquidez saludable · 1.58Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

ABT

Analyst sentiment

Based on 41 analyst votes · 2026-09-05

89/100

Bullish

Hold

Bearish

Precio objetivo

2026-07-30

Bajo

$92.00

Promedio

$123.00

Mediana

$120.50

Alto

$145.00

Resumen de la compañía

IPO: 3/17/1980

Industria: Medical - Devices

P/B i: 2.89

Deuda / Patrimonio i: 0.29

Margen operativo: 18.16%

Margen neto: 14.72%

ROE i: -

ROIC: -

Salud financiera

Puntaje17 / 20

Deuda / Patrimonio: 0.29

Ratio corriente: 1.58

Ratio rápido: 1.18

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Morrone Louis H.

Transacción: 06/30/2026

VENTA

Cambio

-269

Precio

$92.71

Presentación

07/01/2026

Tipo

VENTA

Ahuja Nita

Transacción: 06/30/2026

COMPRA

Cambio

+347

Precio

Not reported

Presentación

07/01/2026

Tipo

COMPRA

Conroy Kevin T

Transacción: 06/30/2026

COMPRA

Cambio

+231

Precio

Not reported

Presentación

07/01/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Morrone Louis H.	VENTA	-269	$92.71	06/30/2026	07/01/2026
Ahuja Nita	COMPRA	+347	Not reported	06/30/2026	07/01/2026
Conroy Kevin T	COMPRA	+231	Not reported	06/30/2026	07/01/2026
Gonzalez Patricia Paola	COMPRA	+363	Not reported	06/30/2026	07/01/2026
Roman Michael F	COMPRA	+416	Not reported	06/30/2026	07/01/2026
Stratton John G	COMPRA	+432	Not reported	06/30/2026	07/01/2026
Cushman Elizabeth C.	VENTA	-560	$94.12	06/27/2026	06/29/2026
Stratton John G	COMPRA	+2,000	$86.82	05/07/2026	06/18/2026
Moreland Mary K	COMPRA	+5,314	$94.41	04/28/2026	04/29/2026
STARKS DANIEL J	COMPRA	+10,000	$92.65	04/27/2026	04/28/2026
Ahuja Nita	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
Babineaux-Fontenot Claire	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
Blount Sally E.	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
Gonzalez Patricia Paola	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
Kumbier Michelle	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
McDew Darren W	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
McKinstry Nancy	COMPRA	+2,305	$91.86	04/24/2026	04/28/2026
McKinstry Nancy	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026
O'Grady Michael	COMPRA	+5,929	$91.86	04/24/2026	04/28/2026
O'Grady Michael	COMPRA	+2,286	Not reported	04/24/2026	04/28/2026

Sobre la compañía

Abbott Laboratories

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.

Fuente - Link

Competidores

BSX GILD ISRG MDT MRK NVO NVS SYK TMO UNH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)

Owning these dividend stocks could be a simple way to make money over the long term.

Fool - Investing News

49 Wealth Management LLC Invests $606,000 in Abbott Laboratories $ABT

49 Wealth Management LLC bought a new stake in Abbott Laboratories (NYSE: ABT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,680 shares of the healthcare product maker's stock, valued at approximately $606,000. A number of other hedge funds also

Defense World

Abbott Laboratories $ABT Shares Sold by Blackhill Capital Inc.

Blackhill Capital Inc. cut its stake in Abbott Laboratories (NYSE: ABT) by 33.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 177,930 shares of the healthcare product maker's stock after selling 90,600 shares during the period. Abbott Laboratories

Defense World

16,128 Shares in Abbott Laboratories $ABT Bought by Bank OZK

Bank OZK purchased a new stake in Abbott Laboratories (NYSE: ABT) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,128 shares of the healthcare product maker's stock, valued at approximately $1,463,000. Several other institutional investors have also added to or reduced their

Defense World

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-04-16	1.14	1.15	0.01
2026-01-22	1.5	1.5	0
2025-10-15	1.3	1.3	0
2025-07-17	1.26	1.26	0
2025-04-16	1.07	1.09	0.02
2025-01-22	1.34	1.34	0
2024-10-16	1.2	1.21	0.01
2024-07-18	1.1	1.14	0.04
2024-04-17	0.955	0.98	0.025
2024-01-24	1.19	1.19	0
2023-10-18	1.1	1.14	0.04
2023-07-20	1.04	1.08	0.04